Latest news with #AppliedDNASciences
Miami Herald
07-07-2025
- Business
- Miami Herald
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
STONY BROOK, NY / ACCESS Newswire / July 7, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that on July 2, 2025, it received written notice (the "Compliance Notice") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00 per share, and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. Nasdaq also notified the Company in the Compliance Notice that the hearing before the Nasdaq Hearings Panel previously scheduled to take place on July 15, 2025, has been cancelled, and the Company's securities will continue to be listed and traded on The Nasdaq Capital Market. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company with over 20 years of experience in developing and commercializing polymerase chain reaction (PCR)-based applications for DNA production. Through its majority-owned subsidiary, LineaRx Inc., the Company is commercializing its LineaDNA and LineaIVT platforms to enable the manufacture of next-generation nucleic acid-based therapies. Visit for more information. Follow us on X and LinkedIn. Forward-Looking Statements The statements made by Applied DNA Sciences in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Actual results could differ materially from those projected due to the Company's history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future ability to continue its listing on the Nasdaq Capital Market, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our LineaDNA and/or LineaIVT platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or LineaIVT platforms, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Reports on Form 10-Q filed on February 13, 2025, and May 15, 2025, and other reports it files with the SEC, which are available at Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. Applied DNA Sciences Contact: Investor Relations contact: Sanjay M. Hurry, 917-733-5573, Web: SOURCE: Applied DNA Sciences, Inc.
USA Today
16-06-2025
- Business
- USA Today
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
Applied DNA Sciences, Inc. (NASDAQ:APDN) ('Applied DNA' or the 'Company'), a leader in PCR-based DNA technologies, today announced that it will resume a regular quarterly investor call schedule, beginning with the release of its fiscal third quarter 2025 financial results in mid-August 2025. In alignment with this resumption, the Company has cancelled its previously scheduled intra-quarter investor call for June 17, 2025. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ('DNA'). Using the polymerase chain reaction ('PCR') to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ('RNAP') for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Applied DNA Sciences Contact: Investor Relations contact: Sanjay M. Hurry, 917-733-5573, Web: SOURCE: Applied DNA Sciences View the original press release on ACCESS Newswire
Business Insider
01-06-2025
- Business
- Business Insider
Upcoming Stock Splits This Week (June 2 to June 6)
These are the upcoming stock splits for the week of June 2 to June 6, based on TipRanks' Stock Splits Calendar. A stock split is corporate move that increases the number of outstanding shares by distributing additional shares to existing shareholders, all without affecting the company's total market value. This typically results in a lower share price, making the stock more accessible, and potentially more attractive, to retail investors. Confident Investing Starts Here: While traditional stock splits aim to broaden appeal by lowering share prices, some companies take the opposite approach. A reverse stock split consolidates shares instead of dividing them, reducing the total count while raising the price per share. The overall market value remains unchanged, but the move is often used to comply with exchange listing requirements, such as Nasdaq's minimum price rule, and prevent delisting. Strategic actions like these, whether to draw in investors or stay listed, often offer signals that savvy traders pay attention to. Let's take a look at the upcoming stock splits for the week. ARB IOT Group (ARBB) – Singapore-based ARB IOT Group provides integrated Internet of Things (IoT) solutions, including smart buildings, industrial automation, and connected agriculture systems. On May 29, the company announced a 1-for-15 reverse stock split as part of its efforts to meet Nasdaq's minimum bid price requirement. The split is set to take effect on June 2. Lyell Immunopharma (LYEL) – Lyell Immunopharma is a clinical-stage biotech company developing T-cell reprogramming therapies for solid tumors. On May 29, the company announced a 1-for-20 reverse stock split as part of its effort to stay in line with Nasdaq's listing requirements. The split takes effect on June 2. Applied DNA Sciences (APDN) – Applied DNA Sciences develops and commercializes DNA-based technologies for therapeutic manufacturing, diagnostics, and supply chain security. On May 29, the company announced a 1-for-15 reverse stock split as part of its efforts to meet Nasdaq's continued listing standards. The split is set to take effect on June 2. Mullen Automotive (MULN) – California-based Mullen Automotive, known for its electric vehicles and battery tech, announced a 1-for-100 reverse stock split on May 29 in a bid to maintain its Nasdaq listing. The split, set to take effect on June 2, is part of the company's effort to meet minimum share price requirements and stay in compliance. Ekso Bionics (EKSO) – Ekso Bionics develops wearable robotic exoskeletons to enhance mobility for people with physical limitations and for industrial use. On May 21, EKSO announced a 1-for-15 reverse stock split to restore compliance with Nasdaq's minimum price rule. The split will take effect on June 2. AGM Group Holdings (AGMH) – AGM Group provides financial technology solutions and manufactures cryptocurrency mining equipment. On May 29, the company announced a 1-for-50 reverse stock split to meet Nasdaq listing criteria. The split will be effective on June 3. ClearOne (CLRO) – ClearOne designs and sells audio-visual communications equipment including microphones, conferencing systems, and network media streaming solutions. On May 21, the company announced a 1-for-15 reverse stock split to regain Nasdaq compliance. The split will be effective on June 2, with trading on a split-adjusted basis starting June 3. Oragenics (OGEN) – Oragenics is a biotechnology company focused on developing novel antibiotics and other treatments for infectious diseases. On May 28, the company announced a 1-for-30 reverse stock split to meet NYSE American listing standards. The split will be effective on June 3.
Miami Herald
30-05-2025
- Business
- Miami Herald
Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, is rescheduling its intra-quarter webcast and investor update call to June 17, 2025, from June 3, 2025, to allow for the implementation of a reverse stock split that will become effective on June 2, 2025. Prepared remarks by members of the Applied DNA management team will be followed by a live question-and-answer session with the Company's sell-side analysts and institutional investors. Webcast and Conference Call Date & Time: Tuesday, June 17 @ 4:30 p.m. Eastern Time Dial In: Domestic callers (toll-free): 844-887-9402International callers: 412-317-6798Canadian callers (toll-free): 866-605-3852Live webcast: A replay of the conference call will be available for 7 days following the conclusion of the call: Replay for domestic callers (toll-free): 877-344-7529, replay access code 3446494Replay for international callers: 412-317-0088, replay access code 3446494Replay for Canadian callers (toll-free): 855-669-9658, replay access code 3446494 An accompanying slide presentation will be embedded in the webcast (live and replay) that will also be accessible as a stand-alone document via the 'Company Presentations' page of the Applied DNA investor relations website. The webcast replay of the call will be available approximately one hour after the end of the call on the 'Company Events' page. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. For additional information: Investor Relations: Sanjay M. Hurry, 917-733-5573, Web: SOURCE: Applied DNA Sciences, Inc.
Miami Herald
14-05-2025
- Business
- Miami Herald
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed concurrently and available on the SEC Filings page of its Investor Relations website. To align with its Annual Meeting of Stockholders on May 22 and ensure a comprehensive post-meeting update, the Company will hold an intra-quarter investor update call on June 3, on which management will discuss the Company's strategic priorities. Webcast and Conference Call Date & Time: Tuesday, June 3 @ 4:30 p.m. Eastern Time Dial In: Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers (toll free): 866-605-3852Live webcast: A replay of the conference call will be available for 7 days following the conclusion of the call: Replay for domestic callers (toll free): 877-344-7529, replay access code 3446494Replay for international callers: 412-317-0088, replay access code 3446494Replay for Canadian callers (toll free): 855-669-9658, replay access code 3446494 An accompanying slide presentation will be embedded in the webcast (live and replay) that will also be accessible as a stand-alone document via the 'Company Presentations' page of the Applied DNA investor relations website. The webcast replay of the call will be available approximately one hour after the end of the call on the 'Company Events' page. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. For additional information:Investor Relations: Sanjay M. Hurry, 917-733-5573, ### SOURCE: Applied DNA Sciences
